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One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for
myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of
severe aplastic anemia (SAA) were identiﬁed in the European Group for Blood and Marrow Transplantation
(EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was
related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of
nonrelapse mortality was 41%. The 5-year overall survival was 45%  9%, better for patients untreated and
patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT
leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Late clonal complications after immunosuppressive
treatment of severe aplastic anemia (SAA) have been well
described [1-9]. These include the development of parox-
ysmal nocturnal hemoglobinuria (PNH) and myelodys-
plastic syndromes (MDS), as well as the transformation to
acute myelogenous leukemia (AML). The incidence of MDS
or AML varies among series from 5% up to 20%; a trans-
formation rate of 10% to 15% is most common. These clonaledgments on page 1450.
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14.05.028complications may occur at any time after treatment. Risk
factors include old age, nonresponse to antithymocyte
globulin (ATG), repeat courses of ATG, use of granulocyte
colony-stimulating factor (G-CSF) with immunosuppressive
treatment and short telomeres. Although several previous
studies have investigated the incidence of these late clonal
complications, there is little information on outcomes of
patients transformed to MDS or AML after treatment of SAA.
The largest series, limited to 17 patients, is from a pediatric
group [10].
Because PNH is a clonal disease but not a malignant dis-
ease, and because the biology and treatment of PNH differ
from that of MDS/AML, the present series was limited to
patients with MDS or AML who transformed from a previous
SAAwithout having undergone previous hematopoietic stem
cell transplantation (HSCT). In this study, we analyzed the
outcomes of patients with SAA transformed to MDS or AML
and treated by HSCT for disease transformation.
Figure 1. Survival of the 140 patients undergoing allogeneic HSCT for MDS/
AML transformed from SAA.
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This study was conducted by the Severe Aplastic Anemia Working Party
(SAAWP) and the Chronic Malignancies Working Party (CMWP) of the Eu-
ropean Group for Blood and Marrow Transplantation (EBMT). For each
transplantation performed, a center reports minimum essential data (MED-
A) to a central database. Many centers report a more comprehensive dataset
(MED-B) as well. Informed consent was obtained locally according to the
regulations applicable at the time of transplantation. Since January 1, 2003,
the EBMT has required centers to conﬁrm that written informed consent has
been obtained before data acceptance. The study included 140 patients from
77 EBMT centers who underwent transplantation over a 22-year period
(1987 to 2009).
Deﬁnitions
Patients were retrieved from the database of the CMWP of the EBMT,
who were recipients of allogeneic HSCT for MDS/AML with a previous
diagnosis of SAA. These patients had received previous immunosuppressive
treatment or supportive care. Second HSCTs were not considered.
Outcomes
The outcomes studied were engraftment, deﬁned as time to the ﬁrst of 3
consecutive days reaching a neutrophil count of 0.5109/L, late graft failure
after initial engraftment, incidence of grade II to IV acute graft-versus-host
disease (GVHD), and incidence of chronic GVHD, using established criteria
for diagnosis of these conditions. Overall survival and relapse incidence
were estimated.
Statistical Analysis
The Kaplan-Meier estimator was used for survival, and the cumulative
incidence function was used for engraftment, acute GVHD, and chronic
GVHD, with death without the event in question serving as the competing
risk. Comparisons were done using the log-rank test. A Cox proportional
hazards regression model was used with backward covariate elimination,
including clinically relevant covariates even if not signiﬁcantly associated
with survival in univariate analysis.
RESULTS
One-hundred and forty patients, including 81 males
(58%), were identiﬁed in the EBMT database of the CMWP.
The median age at time of HSCT was 29 years (range, 1 to
66 years). The median interval from diagnosis of SAA to
transformationwas 65 months (range, 3 to 214 months), and
that from diagnosis of MDS to HSCT was 6 months (range, 2
to 30 months). Of the 140 patients, 104 (74%) were diagnosed
with MDS, and 36 (26%) had transformed to AML. MDS
was classiﬁed as refractory anemia (RA) in 37 cases (26%),
refractory anemia with ringed sideroblasts (RARS) in 18
(13%), RAEB/refractory anemia with excess of blasts in
transformation (RAEBt) in 7 (5%), chronic myelomonocytic
leukemia (CMML) in 4 (3%), and unclassiﬁed in 36 (26%). At
the time of HSCT, 27 patients (19%) were in any complete
remission, 48 (34%) were untreated, 41 (29%) were refractory,
and 24 (17%) were other/unclassiﬁed. All but 2 of the un-
treated patients undergoing HSCT were classiﬁed as having
MDS, but not AML.
Allogeneic HSCT was performed using stem cells from
fully matched sibling (n ¼ 56; 40%), mismatched related
(n¼ 12; 9%), or unrelated donors (n¼ 72; 51%). The stem cell
source was bone marrow in 74 cases (53%), peripheral blood
in 54 cases (39%), and unrelated cord blood in 12 cases (9%).
Conditioning intensity was myeloablative in 110 patients
(79%) and reduced-intensity conditioning (RIC) in 30 (21%).
Sixty-nine (49%) received total body irradiation, of whom 14
(20%) had received low-dose total body irradiation in the
context of RIC. HSCTs were performed between 1987 and
2009 (median, 2002). Median follow-up of surviving patients
was 5 years.
Eighteen patients (12%) experienced primary non-
engraftment, and 1 patient had late graft failure. The cu-
mulative incidence of acute grade II to IV GVHD was 24%(range, 17% to 32%) by 100 days, and the incidence of chronic
GVHD of any degree by 5 years in patients alive at 100 days
was 48% (range, 38% to 60%). The probability of relapse at
5 years was 17% (range, 12% to 25%), and nonrelapse mor-
tality was 41% (range, 33% to 50%). Five-year overall survival
in this cohort was 45%  9% (Figure 1). Survival did not differ
signiﬁcantly by age group (1 to 20, 20 to 40, >40 years), by
disease (MDS, AML), by year of transplantation (before 2000,
after 2000) (Figure 3; Supplementary Data), by donor (sib-
ling, unrelated, mismatched related), stem cell source used
(marrow, peripheral blood, cord blood), or by conditioning
intensity (myeloablative, RIC) but was signiﬁcantly higher in
patients who underwent HSCTwhile in any type of remission
(58%  20%) or untreated (46%  15%) than in patients with
refractory disease (24%  15%) (P ¼ .002 for the comparison
of refractory patients against all other disease stages)
(Figure 2). Causes of death were infection in 15%, GVHD in
12%, organ toxicity in 31%, and graft failure in 4% of the re-
ported deaths.
DISCUSSION
The present series is a series of patients with SAAwho had
transformed to MDS or AML and subsequently underwent
allogeneic HSCT for transformed disease. Transformation of
SAA to MDS or AML is well described and occurs in
approximately 5% to 20% of patients receiving immunosup-
pressive treatment. Whether this transformation is a
consequence of treatment and/or of the original disease has
not yet been determined and is of minor importance for the
present analysis. Because these are rare events, this present
series was accumulated over 22 years and involved
numerous transplantation centers. The main ﬁndings are (1)
45% of patients became long term survivors; (2) treatment-
related mortality was considerable; and (3) the only factor
signiﬁcantly associated with outcome was disease stage
before HSCT, with untreated patients and patients in any
type of remission doing better than patients with refractory
disease. This was the sole factor signiﬁcantly associated with
survival in both univariate and multivariate analyses; thus,
details of the multivariate analysis are not shown. Obviously,
selecting patients who have received chemotherapy without
responding would result in a negatively selected cohort
bound to have unfavorable outcomes.
Figure 2. Survival of patients undergoing HSCT with refractory disease
compared with those undergoing HSCT while in any type of remission or with
untreated disease (P ¼ .002).
A.A. Hussein et al. / Biol Blood Marrow Transplant 20 (2014) 1435e14541450Of note, the majority of donors used were unrelated. This
is not surprising, especially in younger patients, given that
those at risk of developing secondary MDS after treatment of
SAA would have most commonly received a sibling donor
graft at the time of diagnosis of SAA, had there been a good
donor available.
The 17% relapse rate for our cohort appears to be lower
than that for similar cohorts of patients undergoing trans-
plantation for MDS not associated with SAA. Whether this
reﬂects the fundamental biology of this disease or is related
to the rather young age of patients with SAA that transforms
to MDS/AML cannot be answered by our data. The rate of
nonrelapse mortality is considerable and needs to be low-
ered. There was a high proportion of deaths related to
toxicity (23 of 71 deaths; 32%), most likely explained by the
use of intensive conditioning in patients with many previous
transfusions and possibly iron overload. Another possible
explanation for increased toxicity is that the original bone
marrow failure for which the patient had been treated was
part of an inherited but unrecognized marrow failure syn-
drome, such as a telomeropathy or Fanconi anemia, making
the patient more prone to conditioning-related toxicity.
These possibilities should be carefully excluded before the
initiation of conditioning, even in adult patients [11].
Our graft failure rate of 12% is rather high, considering
that a large majority of the patients received myeloablative
conditioning. This high rate of failuremight be attributable to
previous transfusions in many patients, leading to alloim-
munization. Although we lack data on the number of trans-
fusions received or the presence of pretransplantation
anti-HLA antibodies, the median disease duration of more
than 65months before transformation toMDS/AML indicates
that most patients most likely received multiple trans-
fusions. Only 4% of deaths were attributed to nonengraft-
ment, possibly related to autologous recovery or rescue
treatment.
Owing to this study’s retrospective nature, data on this is
lacking, and these and other factors such as patient age and
comorbidities need careful evaluation before choosing amyeloablative or RIC regimen for a given patient. The use of
RIC regimens was not associated with better survival; how-
ever, we lack knowledge on how patients were selected for
one or the other type of regimen.
This study has other limitations as well. We do not have
detailed knowledge of the pretransplantation treatment of
SAA for the majority of patients; however, we do know that
none had undergone previous HSCT. This series spans
22 years, and many factors affecting transplantation out-
comes have changed over the years; however, year of HSCT
did not affect survival in this series. Our study also lacks data
on how many patients received pretransplantation chemo-
therapy, with the inherent risk of failure to recover hema-
tologic counts after chemotherapy on a background of
previous SAA. Finally, patients, types of transformed disease,
and treatment strategies were quite heterogeneous. Never-
theless, we report that of 140 patients undergoing allogeneic
HSCT for MDS/AML transformed from SAA, 45%were rescued
long term.
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